Matthew Lang

CIK: 0001712069

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (80.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (20.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

GPCR

Structure Therapeutics Inc.

Officer

MTSR

Metsera, Inc.

Officer

LYEL

Lyell Immunopharma, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

GPCR
Structure Therapeutics Inc.
Apr 15, 2026
Award(A)
Direct
184.6K shares-
MTSR
Metsera, Inc.
Nov 13, 2025
Disposition(D)
Direct
12.5K shares-
MTSR
Metsera, Inc.
Nov 13, 2025
Award(A)
Restricted Stock Unit
Direct
12.5K shares-
MTSR
Metsera, Inc.
May 20, 2025
Award(A)
Stock Option (Right to Buy)
Direct
46.9K shares-
LYEL
Lyell Immunopharma, Inc.
Feb 10, 2025
Award(A)
Direct
112.5K shares-

		Type	Shares	Price		Ownership
Apr 15, 2026	GPCR Structure Therapeutics Inc.	Award(A)	184,614	-	$0	Direct
Nov 13, 2025	MTSR Metsera, Inc.	Disposition(D)	12,500	-	-	Direct
Nov 13, 2025	MTSR Metsera, Inc.	Award(A) Restricted Stock Unit	12,500	-	-	Direct
May 20, 2025	MTSR Metsera, Inc.	Award(A) Stock Option (Right to Buy)	46,875	-	-	Direct
Feb 10, 2025	LYEL Lyell Immunopharma, Inc.	Award(A)	112,500	-	-	Direct

1-5 of 5 transactions

About Lang Matthew

Lang Matthew (SEC CIK 0001712069) files insider reports with the SEC as COO & GC of Structure Therapeutics Inc. (GPCR), Chief Legal Officer of Metsera, Inc. (MTSR) and Chief Business Officer of Lyell Immunopharma, Inc. (LYEL).

Signal8 holds 6 ownership filings by Lang Matthew (2 Form 3, 4 Form 4), filed between Feb 26, 2025 and Apr 23, 2026. Those filings report 5 transactions, from Feb 10, 2025 to Apr 15, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Lang Matthew's filings is in SOUTH SAN FRANCISCO, CA.

Recent filings by Lang Matthew

Apr 15, 2026: Grant or award of GPCR shares (Form 4, code A).
Nov 13, 2025: Disposition to issuer transaction of MTSR shares (Form 4, code D).
Nov 13, 2025: Grant or award of MTSR derivative securities (Form 4, code A).
May 20, 2025: Grant or award of MTSR derivative securities (Form 4, code A).
Feb 10, 2025: Grant or award of LYEL shares (Form 4, code A).

Other insiders filing for Structure Therapeutics Inc. (GPCR)

Coll Crespo Blas, CHIEF MEDICAL OFFICER
Lin Xichen, CHIEF SCIENTIFIC OFFICER
Berrios John Joseph, Chief Commercial Officer
FMR LLC, 10% Owner
Russell Angus C., Director
LOVE TED W, Director

How to read Form 4 transaction codes